Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
Tingting Yan, Nana Yan, Ping Wang, et al.
Acta Pharmaceutica Sinica B (2019) Vol. 10, Iss. 1, pp. 3-18
Open Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

Treatment for liver cancer: From sorafenib to natural products
Shuli Man, Chen Luo, Mengyao Yan, et al.
European Journal of Medicinal Chemistry (2021) Vol. 224, pp. 113690-113690
Closed Access | Times Cited: 138
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Hao Chen, Huabing Tan, Juan Wan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108391-108391
Closed Access | Times Cited: 113
Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
Karli R. LeFort, Wiramon Rungratanawanich, Byoung‐Joon Song
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 36
Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
Hongcai Li, Jingjing Liang, Mengzhen Han, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 19
Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice
Lili Ding, Qiaoling Yang, Eryun Zhang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 6, pp. 1541-1554
Open Access | Times Cited: 73
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong, Dongjie Li, Hongbo Meng, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 9, pp. 3650-3666
Open Access | Times Cited: 69
Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling
Tian Lan, Shuo Jiang, Jing Zhang, et al.
Hepatology (2021) Vol. 76, Iss. 1, pp. 155-171
Open Access | Times Cited: 63
Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
Haowen Xu, Jiahao Chen, Pan Chen, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 2, pp. 678-693
Open Access | Times Cited: 57
Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds
Tianyu Wang, Jingjing Liu, Xialin Luo, et al.
Pharmacology & Therapeutics (2021) Vol. 224, pp. 107824-107824
Closed Access | Times Cited: 56
Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease
Jacob W. Ballway, Byoung‐Joon Song
Antioxidants (2021) Vol. 10, Iss. 3, pp. 384-384
Open Access | Times Cited: 56
Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates
Noel Salvoza, Pablo J. Giraudi, Claudio Tiribelli, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2764-2764
Open Access | Times Cited: 41
Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress
Pin Gong, Hui Long, Yuxi Guo, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116927-116927
Closed Access | Times Cited: 32
Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development
Lu Wang, Yonghuan Yan, Linfang Wu, et al.
Pharmacological Research (2023) Vol. 196, pp. 106925-106925
Open Access | Times Cited: 28
Aescin can alleviate NAFLD through Keap1-Nrf2 by activating antioxidant and autophagy
Hao Yu, Siru Yan, Meiyu Jin, et al.
Phytomedicine (2023) Vol. 113, pp. 154746-154746
Closed Access | Times Cited: 25
Berberine prevents NAFLD and HCC by modulating metabolic disorders
Xinyue Lin, Jilei Zhang, Yajun Chu, et al.
Pharmacology & Therapeutics (2024) Vol. 254, pp. 108593-108593
Closed Access | Times Cited: 13
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions
Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny, et al.
Life Sciences (2021) Vol. 271, pp. 119220-119220
Closed Access | Times Cited: 52
Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease
Honglin Zhou, Cheng Ma, Cheng Wang, et al.
European Journal of Pharmacology (2021) Vol. 898, pp. 173976-173976
Closed Access | Times Cited: 51
Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation
Hao Chen, Tong Nie, Penglu Zhang, et al.
Life Sciences (2022) Vol. 296, pp. 120428-120428
Closed Access | Times Cited: 33
Theabrownin and Poria cocos Polysaccharide Improve Lipid Metabolism via Modulation of Bile Acid and Fatty Acid Metabolism
Jieyi Wang, Dan Zheng, Fengjie Huang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 33
Berberine in Non-Alcoholic Fatty Liver Disease—A Review
Anna Koperska, Agnieszka Wesołek, Małgorzata Moszak, et al.
Nutrients (2022) Vol. 14, Iss. 17, pp. 3459-3459
Open Access | Times Cited: 33
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose–response meta-analysis of randomized controlled trials
Mahdi Vajdi, Shirin Hassanizadeh, Reza Hassanizadeh, et al.
Nutrition Reviews (2024)
Closed Access | Times Cited: 7
A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways
Md. Rezaul Islam, Abdur Rauf, Shopnil Alash, et al.
Medical Oncology (2024) Vol. 41, Iss. 6
Closed Access | Times Cited: 7
Lactobacillus Casei-fermented Amomum Xanthioides Mitigates non-alcoholic fatty liver disease in a high-fat diet mice model
Seung‐Ju Hwang, Yujin Choi, Jing‐Hua Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116250-116250
Open Access | Times Cited: 6
Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Jiashu Pan, Wenjun Zhou, Ruohui Xu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113127-113127
Open Access | Times Cited: 28
Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway
Siran Yue, Yi-Yun Tan, Lei Zhang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top